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Abstract
Following a request from the European Commission, the EFSA Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety
and efﬁcacy of Lavipan® (Lactococcus lactis B/00039, Carnobacterium divergens KKP 2012p,
Lactobacillus casei B/00080, Lactobacillus plantarum B/00081 and Saccharomyces cerevisiae KKP
2059p) when used as a zootechnical additive for weaned piglets, chickens and turkeys for fattening at
the minimum dose of 5 x 108 colony forming unit (CFU) lactic acid bacteria (LAB)/kg feed and
5 x 106 CFU S. cerevisiae/kg feed. The species Lc. lactis, C. divergens, Lb. casei, Lb. plantarum and
S. cerevisiae are considered by EFSA to be suitable for the qualiﬁed presumption of safety (QPS)
approach to safety assessment and not to require speciﬁc demonstration of safety other than
demonstrating the absence of resistance to antibiotics of human and veterinary signiﬁcance. The identity
of all strains has been established and no antibiotic resistance of concern detected. Following the QPS
approach to safety assessment, these strains are presumed safe for the target species, consumers of
products from animals fed the additive and the environment. Lavipan® is not toxic by inhalation or a
dermal/ocular irritant, but should be considered as a potential respiratory sensitiser. In the absence of
data, no conclusion can be drawn on the skin sensitisation potential. Lavipan® has the potential to
improve the performance of chickens for fattening when supplemented at the recommended dose of
5 x 108 CFU LAB/kg feed and 5 x 106 CFU S. cerevisiae/kg feed. No conclusions can be drawn on the
efﬁcacy of Lavipan® when added to feed for weaned piglets or turkeys for fattening. Lavipan® is
compatible with diclazuril, salinomycin sodium, decoquinate, maduramicin and narasin+nicarbazin.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from JHJ Ltd2 for the authorisation of the product
Lavipan® (Lactococcus lactis B/00039, Carnobacterium divergens KKP 2012p, Lactobacillus casei
B/00080, Lactobacillus plantarum B/00081 and Saccharomyces cerevisiae KKP 2059p),3 when used as
a feed additive for piglets (weaned), chickens for fattening and turkeys for fattening (category:
zootechnical additives; functional group: gut ﬂora stabilisers).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). EFSA received directly from the
applicant the technical dossier in support of this application. The particulars and documents in support
of the application were considered valid by EFSA as of 31 July 2014.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of Lavipan®
(Lactococcus lactis B/00039, Carnobacterium divergens KKP 2012p, Lactobacillus casei B/00080,
Lactobacillus plantarum B/00081 and Saccharomyces cerevisiae KKP 2059p), when used under the
proposed conditions of use (see Section 3.1.4).
1.2. Additional information
The additive Lavipan® is a preparation containing viable cells of Lc lactis B/00039, C. divergens KKP
2012p, Lb. casei B/00080, Lb. plantarum B/00081 and S. cerevisiae KKP 2059p. It has not been
previously authorised as a feed additive in the European Union (EU).
The species Lc. lactis, Lb. casei, Lb. plantarum, C. divergens and S. cerevisiae are considered by
the EFSA to be suitable for the qualiﬁed presumption of safety (QPS) approach to safety assessment
(EFSA, 2007; EFSA BIOHAZ Panel, 2013, 2014). This approach requires the identity of the strain to be
conclusively established and evidence that the strain does not show resistance to antibiotics of human
and veterinary importance.
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier4 in support of the authorisation request for the use of Lavipan® as a feed additive. The
technical dossier was prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003,
Regulation (EC) No 429/20085 and the applicable EFSA guidance documents.
EFSA has veriﬁed the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of the active agents in animal feed. The Executive Summary of the EURL
report can be found in Annex A.
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 JHJ LTD. Nowa Wies 11, 63–308, Gizałki, Poland.
3 In the mandate, the applicant identiﬁed the strains with in-house identiﬁers: Lactococcus lactis IBB500, Carnobacterium
divergens S1, Lactobacillus casei ŁOCK 0915, Lactobacillus plantarum ŁOCK 0862 and Saccharomyces cerevisiae ŁOCK 0141.
4 FEED dossier reference: FAD-2013-0048.
5 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
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2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Lavipan® is in
line with the principles laid down in Regulation (EC) No 429/2008 and the relevant guidance
documents: Guidance on zootechnical additives (EFSA FEEDAP Panel, 2012a), Technical guidance:
Tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011), Guidance on studies
concerning the safety of use of the additive for users/workers (EFSA FEEDAP Panel, 2012b), Technical
Guidance: extrapolation of data from major species to minor species regarding the assessment of
additives for use in animal nutrition (EFSA, 2008a), Guidance on the assessment of bacterial
susceptibility to antimicrobials of human and veterinary importance (EFSA FEEDAP Panel, 2012c), and
Technical guidance – compatibility of zootechnical microbial additives with other additives showing
antimicrobial activity (EFSA, 2008b).
3. Assessment
The additive Lavipan® is a preparation containing viable cells of Lc. lactis B/00039, C. divergens
KKP 2012p, Lb. casei B/00080, Lb. plantarum B/00081 and S. cerevisiae KKP 2059p intended for use
as a feed additive for weaned piglets, and chickens and turkeys for fattening (category: zootechnical
additives; functional group: gut ﬂora stabilisers).
3.1. Characterisation
3.1.1. Characterisation of the active agents
The Lc. lactis strain was isolated from cow’s milk and is deposited in the Polish Collection of
Microorgansims (PCM) with the accession number B/00039.6 The C. divergens strain was isolated from
the digestive system of a common carp and is deposited in the Polish Collection of Industrial
Microorganisms with the accession number KKP 2012p.7 The Lc. casei strain, isolated from milk
fermented drinks, and the Lb. plantarum strain, isolated from silage, are deposited in the PCM with the
accession numbers B/00080 (Lc. casei)8 and B/00081 (Lb. plantarum),9 respectively. The S. cerevisiae
strain, isolated from silage, is deposited in the Polish culture Collection of Industrial Microorganisms
with the accession number KKP 2059p.10
The bacterial strains were identiﬁed using the complete sequence of 16S rRNA gene and species
speciﬁc primers pairs while the S. cerevisiae by means of the internal transcribed spacer region
sequence.11
The bacterial strains were tested for antibiotic susceptibility using commercial agar diffusion
techniques. The battery of antibiotics used included those recommended by EFSA (EFSA FEEDAP
Panel, 2012c).12 The minimum inhibitory concentration (MIC) values for the C. divergens strain were
compared to the cut-off values for facultative heterofermentative Lactobacillus which is considered by
the Panel as the closest group documented in the Guidance. The MIC values for all strains were below
or equal to the EFSA cut-off values with the exception of Lc. lactis for which the MIC for streptomycin
was exceeded by a single dilution. This is within the normal variation around the mean, and thus, does
not raise concerns for safety.
3.1.2. Manufacturing process and characterisation of the additive13
The manufacturing process is detailed in the dossier.
6 Technical dossier/Section II/Annex II_19.
7 Technical dossier/Section II/Annex II_20.
8 Technical dossier/Supplementary information May 2015/Annex 1/Annex 1.II.
9 Technical dossier/Supplementary information May 2015/Annex 1/Annex 1.I.
10 Technical dossier/Supplementary information May 2015/Annex 1/Annex 1.III.
11 Technical dossier/Section II/Annexes II_23-27.
12 Technical dossier/Supplementary information May 2015/Annex 2.
13 This section has been amended following the conﬁdentiality claims made by the applicant.
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The applicant declares a minimum speciﬁcation of 1 x 109 colony forming unit (CFU) lactic acid
bacteria (LAB)/g and > 1 x 107 CFU S. cerevisiae/g and speciﬁcally:14
• Lc. lactis ≥ 5 x 108 CFU/g
• Lb. plantarum ≥ 3 x 108 CFU/g
• Lb. casei ≥ 1 x 108 CFU/g
• C. divergens ≥ 3 x 108 CFU/g
• S. cerevisiae ≥ 1 x 107 CFU/g
Batch-to-batch variation tested on six batches and based on individual counts showed that
speciﬁcations were always exceeded:15
• Lc. lactis: mean = 4.4 x 109 CFU/g, range = 1.0–13 x 109 CFU/g
• Lb. plantarum: mean = 3.3 x 109 CFU/g, range = 1.1–13 x 109 CFU/g
• Lb. casei: mean = 3.7 x 109 CFU/g, range = 1.1–12 x 109 CFU/g
• C. divergens: mean = 3.3 x 109 CFU/g, range = 1.1–12 x 109 CFU/g
• S. cerevisiae: mean = 3 x 109 CFU/g, range = 1–4 x 109 CFU/g
Tests of additional three batches showed compliance with speciﬁcations based on total lactobacilli
and yeast counts.16
Certiﬁcates of analysis of at least three batches of the additive for chemical contaminants (aﬂatoxins
B1, B2, G1, G2, zearalenone, ochratoxin A, deoxynivalenol, heavy metals and arsenic) and for
microbiological contaminants were submitted. Action limits have been set for lead (< 10 mg/kg),
cadmium (< 0.5 mg/kg), mercury (< 0.1 mg/kg), arsenic (< 4 mg/kg), ﬁlamentous fungi (< 100 CFU/g),
Escherichia coli (absence in 1 g) and Salmonella (absence in 25 g). Analyses demonstrated compliance
with these limits.17 No speciﬁcations were set for mycotoxins. Levels found were all lower than the limit
of detection (LOD) of the methods for aﬂatoxins B1, B2, G1 and G2 and zearalenone.18 For
deoxynivalenol, two batches were below the LOD,19 and in one case, the value measured was 24.3 lg/kg.
For ochratoxin A, analysis showed values of 1.10 lg/kg, 1.60 lg/kg and < 0.12 lg/kg (LOD).17
One batch of Lavipan® was examined for particle size distribution by laser diffraction and dusting
potential with a Heubach dustometer.20 Results showed that 4.4% by volume of the additive consists
of particles with diameters below 50 lm and no particles with diameter below 10 lm were present.
The dusting potential was 0.01 g/m3.
3.1.3. Stability and homogeneity
3.1.3.1. Shelf life
The shelf life of each separate strain composing the additive (apparently one batch of each,
12 replicates) was tested at two conditions (4°C/relative humidity (RH) 35% and 20°C/RH 50%) for
12 months.21 Bacterial counts’ losses were < 0.5 log over the full experimental period when samples
were retained in its original packaging at 20°C. In case of the yeast counts, 1 log reduction was
observed at 20°C/RH 50% after 1 month. Data on the individual strains is considered to represent
their behaviour when included in the additive.
3.1.3.2. Stability in premixtures and feedingstuffs
The applicant declares that Lavipan® is not suitable for use in vitamins/minerals premixtures.22
To test the stability in mash feed, a study with feed for turkeys was conducted including three
batches of a mixture of the strains composing Lavipan® in a proportion mimicking its composition.23
The samples were stored at two conditions (4°C/RH 50% and 20°C/RH 35%), and LAB and yeasts
counts made at 2 week intervals for up to 3 months. The total counts of LAB remained constant
14 Technical dossier/Supplementary information May 2015/Annex 3.
15 Technical dossier/Section II/Annex II_2.
16 Technical dossier/Section II/Annex II_3.
17 Technical dossier/Section II/Annex II_4-18.
18 Limits of detection: for aﬂatoxins B1, B2, G1 and G2: < 0.21 lg/kg and for zearalenone: < 0.78 lg/kg.
19 Limit of detection for deoxynivalenol < 4.33 lg/kg.
20 Technical dossier/Supplementary information May 2015/Annexes 4.
21 Technical dossier/Supplementary information May 2015/Annex 6.
22 Technical dossier/Supplementary information May 2015/Annex 7.
23 Technical dossier/Supplementary information November 2015/Annex 1.
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(losses < 0.5 log) in all three batches when the product was stored at 20°C/RH 35% up to 4 weeks,
while more than 1 log reduction was observed after 12 weeks. All the data presented refer to total
counts of LAB and not to the single strains. Considering the short shelf life of the additive, the FEEDAP
Panel does not expect relevant differences among the bacterial strains. Viable cell counts of the yeast
remained unchanged (losses < 0.5 log) at 4°C/RH 50% over 8 weeks and at 20°C/RH 35% over
2 weeks, while a 2 log reduction was observed after 12 weeks.
The stability of the mix of the four LAB strains and the yeast strain (three batches) to pelleting of
feed (composition not described) was measured. Counts of total LAB and yeasts in feed were
determined before and after the pelleting process at 60, 70 and 80°C.24 Although the total counts
were not signiﬁcantly affected by the heat treatment (losses < 0.5 log), survivability of the individual
bacterial strains was not determined. Counts of viable cells of the yeast strain remained unchanged
(losses ≤ 0.5 log) after treatment at all conditions.
A study was conducted with feed for piglets, mixed with the individual cultures in a proportion in
accordance with the manufacturing process of Lavipan® and the resulting mixture was subject to
pelleting (75°C).25 The pelleted feed was stored at two conditions (4°C/RH 50% and 20°C/RH 35%)
over 3 months. The counts in the pelleted feed remained unchanged (losses < 0.5 log) at 4°C over
12 weeks. In contrast, at 20°C during the ﬁrst 4 weeks, the counts of viable cells decreased for at
least 1 log for all strains except Lc. lactis. In an additional study, stability of the complete additive
(three batches) mixed with pelleted feed for turkeys was monitored during storage at 4°C/RH 50%
and 20°C/RH 35%.26 In this case, counts of total LAB and of yeast were made over a 12 week period.
Counts of LAB remained unchanged (losses < 0.5 log) at 4°C/RH 50% over 12 weeks and at 20°C/RH
35% over 4 weeks. Counts of the yeast remained unchanged (losses < 0.5 log) at 4°C/RH 50% over
8 weeks and at 20°C/RH 35% over 4 weeks.
Overall, although the additive appears to resist pelleting, stability in complete feed (mash or
pelleted) can only be assured for 3 months when the feed is stored at 4°C.
3.1.3.3. Homogeneity
The capacity of Lavipan® to homogeneously mix with feed was measured in three batches of a
feed (composition not provided). Each batch was divided into 10 subsamples.27 Cell counts showed a
coefﬁcient of variation (CV) < 15% for both total LAB and yeasts.
3.1.4. Conditions of use
Lavipan® is intended to be used in diets for weaned piglets, chickens for fattening and turkeys for
fattening at the minimum dose of 500 mg/kg feed equating to 5 x 108 CFU LAB/kg feed and
5 x 106 CFU S. cerevisiae/kg feed.
Lavipan® is not suitable for use in vitamins/minerals premixtures.
The applicant intends to use Lavipan® in conjunction with some coccidiostats (diclazuril,
salinomycin sodium, decoquinate, maduramicin and narasin+nicarbazin).
3.2. Safety
3.2.1. Safety for the target species, the consumer and the environment
In the view of the FEEDAP Panel, the identity of the strains of Lc. lactis, Lb. plantarum, Lb. casei,
C. divergens and S. cerevisiae has been established and the antibiotic resistance qualiﬁcation of the bacterial
strains has been met. Accordingly, these strains are considered by EFSA to be suitable for the QPS approach
to safety assessment (EFSA, 2007; EFSA BIOHAZ Panel, 2013, 2014) and are presumed safe for the target
species, consumers of products from animals fed the additive and the environment.
3.2.2. Safety for the user
An acute inhalation toxicity study on rats was performed according to Organisation for Economic
Co-operation and Development (OECD) Technical Guideline 403.28 Wistar rats were exposed to the
24 Technical dossier/Supplementary information November 2015/Annex 3.
25 Technical dossier/Supplementary information May 2015/Annex 8.
26 Technical dossier/Supplementary information November 2015/Annex 2.
27 Technical dossier/Supplementary information November 2015/Annex 4.
28 Technical dossier/Supplementary information May 2015/Annex 10/Annex 10_IV.
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additive at the highest attainable concentration, i.e. 0.34 mg/L for 4 h in a nose-only inhalation
chamber. No clinical signs were observed in any of the animals after a 14 day-observation period. This
result indicated that the test material was not toxic by inhalation.
A small fraction of the product (≥ 4%) has a diameter below 50 lm, and although the dusting
potential is low, there is a potential exposure of the upper respiratory tract. Given the proteinaceous
nature of the active agents, the additive should be considered to be a potential respiratory sensitiser.
Lavipan® was tested in studies of irritancy to skin of Wistar rats and to eyes of New Zealand White
rabbits according to OECD Technical Guidelines 402 and 405, respectively. The results of the studies of
skin irritancy gave no indication that the additive causes irritation to skin.29 In the eye irritancy study,
Lavipan® caused an initial reddening of the conjunctiva followed by some swelling of the conjunctiva
and moderate discharge from the eye that disappeared after 48 h.30 This result indicated that the test
material was not irritant to eye.
No data are available on skin sensitisation for Lavipan®.
3.2.2.1. Conclusions on safety for the user
Lavipan® is not toxic by inhalation or a dermal/ocular irritant, but should be considered as a
potential respiratory sensitiser. In the absence of data, no conclusion can be drawn on the skin
sensitisation potential.
3.3. Efﬁcacy
3.3.1. Efﬁcacy for weaned piglets
Overall six studies with weaned piglets, conducted in the same Member State but in different
locations were submitted. One study31 was disregarded because the initial weight of the control group
was signiﬁcantly smaller than that of the treated animals, introducing a bias in the study. Other three
studies,32 with a very similar experimental design, were submitted upon detailed request. However, the
detailed information needed to fully assess the studies was not provided (e.g. absence of overall feed
intake data, absence of the average initial and ﬁnal weights, uncertainty about experimental unit (pig
or pen), inadequate statistical reporting). Therefore, the FEEDAP Panel was unable to conclude on
these studies. The remaining two studies are described below.
The ﬁrst of the two remaining studies involved 96 weaned piglets (average age 31 days, average
initial body weight (bw) 8.2 kg, synthetic line) distributed in two treatment groups (control and
Lavipan®).33 Each group was replicated six times, each pen involving eight piglets (four males and
four females). The trial lasted 42 days during which the piglets received a basal prestarter diet for
14 days and a growing diet for the following 28 days, ad libitum. The diet of the Lavipan® group was
supplemented with the additive at the minimum recommended dose (5 x 108 CFU LAB/kg feed and
5 x 106 CFU S. cerevisiae/kg feed, conﬁrmed by analysis). Individual body weight at the start and at
14 and 42 days after weaning, feed intake per pen and per feeding phase and overall were measured,
and average daily gain and feed to gain ratio were also calculated. Morbidity and mortality were also
monitored. The data were analysed with analysis of variance (ANOVA) using age and initial weight as
covariates.
One animal in the Lavipan® group died. No signiﬁcant differences on the performance of piglets
were observed. The ﬁnal body weight was ~ 24.5 kg and the average weight gain was ~ 385 g/pig/day.
Despite the request, no data on feed intake or feed to gain ratio were provided for the overall period.
The second study involved 256 piglets (27 days of age, average initial body weight 7.8 kg,
synthetic line) randomly allocated according to sex and weight to four treatment groups, each
replicated eight times (each replicate consisting of four males and four females).34 The experimental
groups resulted from the supplementation of the basal diet with Lavipan® at the intended doses of
5 x 107, 5 x 108 and 5 x 109 CFU/kg. Although it was not speciﬁed what these counts refer to, it is
assumed they refer to total LAB. Piglets were fed ad libitum a prestarter and starter diet based on
barley/wheat/maize, in pelleted form. The trial lasted 49 days. The parameters measured were body
29 Technical dossier/Supplementary information May 2015/Annex 10/Annex 10_III.
30 Technical dossier/Supplementary information May 2015/Annex 10/Annex 10_I.
31 Technical dossier/Supplementary information May 2015/Annex 11 i 12/Annex 1112I.
32 Technical dossier/Supplementary information November 2015/Annexes 5.1, 5.2 and 5.3.
33 Technical dossier/Section IV/Annex IV.1.
34 Technical dossier/Supplementary information May 2015/Annex 11 i 12/Annex 1112II.
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weight (on days 0, 14, and 49 days) and feed intake per pen. Morbidity and mortality were monitored
and average daily gain and feed to gain ratio (per pen) calculated. The data were subject to ANOVA
with initial weights as covariant.
Mortality and culling were low (3%) and apparently were not inﬂuenced by treatment (one animal
from the control was removed, one from the 5.4 x 107 CFU/kg feed group died, two from the
5.2 x 108 CFU/kg feed group died and from the group at 4.8 x 109 CFU/kg feed, three were excluded
and one died). No signiﬁcant differences in performance were found in the overall period. The ﬁnal
body weight was ~ 30 kg, average daily weight gain ~ 460 g/pig per day, daily feed intake ~ 780 g/pig
per day and feed to gain ratio ~ 1.7. Use of a single value for CFUs does not relate to the
speciﬁcations provided for the additive.
3.3.1.1. Conclusions on efﬁcacy for weaned piglets
None of the studies provided showed an effect of the additive on the performance of the animals.
3.3.2. Efﬁcacy for chickens for fattening
Four studies with chickens for fattening conducted in the same Member State but in two different
locations were presented.
In all cases, 1-day-old Ross 308 birds (females and males 1:1 in studies 135 and 2,36 males in study
337 and females in study 438) were fed ad libitum mash diets based on wheat/maize/soybean meal,
containing salinomycin during an experimental period of 35–42 days. Studies considered two or more
experimental groups, one receiving the basal diet not supplemented with the additive and the others
receiving the same basal diet supplemented with the additive at different inclusion rates. Study 1
included one Lavipan® group receiving the diet supplemented with the additive at the recommended
dose (5 x 108 CFU LAB/kg feed and 5 x 106 CFU S. cerevisiae/kg feed). Study 2 included two
diets supplemented with Lavipan® to levels of LAB/S. cerevisiae of 5 x 107/5 x 105 CFU/kg feed or
5 x 108/5 x 106 CFU/kg feed (the recommended dose). Study 3 included three Lavipan® diets
supplemented with the additive to levels of LAB/S. cerevisiae of: 5 x 108/5 x 106 CFU/kg feed (the
recommended dose), 5 x 109/5 x 107 CFU/kg feed or 5.5 x 1010/5.5 x 108 CFU/kg feed (Table 1). In
all cases, doses were conﬁrmed by analysis of feed.39 In study 4, there were three Lavipan® diets
containing the additive at the intended doses of 5 x 107, 5 x 108 or 5 x 109 CFU/kg. Although, no
differential counts were speciﬁed, it is assumed that they refer to total LAB. Doses were not conﬁrmed
by analysis. Birds were weighed on a weekly basis on the ﬁrst three studies and at days 14 and 41 in
study 4. Feed intake, morbidity and mortality were monitored and feed to gain ratio calculated.
However, the feed intake data were not reported in the ﬁrst three studies. Data were analysed using
ANOVA and Duncan’s test using the pen as experimental unit. Results are presented in Table 1.
Table 1: Summary of performance data of chickens receiving Lavipan®
Trial
no
Duration of
the trial
(days)
Total number of
animals
Additive CFU
(LAB/S. cerevisiae)/
kg feed(1)
Feed
intake
(kg)
Final
weight
(kg)
Feed:
gain
Mortality
(%)
No of replicates per
treatment 3 No of
animals per
replicate
1 42 400 0 n.r. 2.66a 1.74 1.5
4 x 50 5 x 108/5 x 106 n.r. 2.76b 1.71 1.5
2 41 750 0 n.r. 2.70a 1.59 1.2
5 x 50 5 x 107/5 x 105 n.r. 2.82b 1.57 0.4
5 x 108/5 x 106 n.r. 2.84b 1.56 1.2
35 Technical dossier/Section IV/Annex IV.2.
36 Technical dossier/Supplementary information May 2015/Annex 13/Annex 13.I.
37 Technical dossier/Supplementary information November 2015/Annex 7.
38 Technical dossier/Supplementary information May 2015/Annex 13/Annex 13.II.
39 Technical dossier/Supplementary information November 2015/Annex 6.
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Mortality was not inﬂuenced by treatment in any of the studies. Birds from the Lavipan® group
showed a signiﬁcantly greater body weight than those in the control group in the ﬁrst three studies.
Feed to gain ratio was also signiﬁcantly improved in study 3 (feed intake data not given). No
parameter was inﬂuenced by treatment in study 4. In addition, in this study, use of a single value for
CFU does not relate to the speciﬁcations provided for the additive.
The FEEDAP Panel notes that in study 3 chickens were kept in cages (two birds per cage, size of
cages was not reported). Although this does not reﬂect current European production practices, the
nature of the housing is unlikely to have affected the biological response to the additive.
3.3.2.1. Conclusions on efﬁcacy for chickens for fattening
The FEEDAP Panel concludes that Lavipan® at the recommended dose (5 x 108 CFU LAB/kg feed
and 5 x 106 CFU S. cerevisiae/kg feed) has the potential to increase ﬁnal body weight of chickens for
fattening.
3.3.3. Efﬁcacy for turkeys for fattening
Four studies with turkeys for fattening conducted in the same Member State but in three different
locations were submitted. However, two studies were not considered, one study40 due to the lack of
replications and the other41 due to incomplete reporting of data and because birds entered the study
at 3 weeks of age.
The ﬁrst of the remaining studies involved 300 turkeys for fattening (BIG 6, females, 1-day-old)
distributed into three treatment groups, each replicated ﬁve times.42 The diets of the treatment groups
included no additive (control) or Lavipan® to levels of LAB/S. cerevisiae of 5 x 107/5 x 105 CFU/kg
feed or 5 x 108/5 x 106 CFU/kg feed (the recommended dose). Doses were conﬁrmed by analysis of
feed.43 Birds were fed ad libitum the diets in mash form based on wheat/corn/soybean meal. All diets
contained a coccidiostat (diclazuril). The trial lasted 105 days. Body weight of birds was measured on
a weekly basis. Feed intake and mortality were also monitored and feed to gain calculated. However,
data on feed intake were not provided. Data were analysed using one-way ANOVA and Duncan’s test
considering the pen as experimental unit.
Mortality was low (control = 5, Lavipan® = 4 and 5) and not treatment related. The turkeys fed
with Lavipan® at both doses showed a signiﬁcantly greater ﬁnal body weight than those of the control
group (9.27 vs 9.53 and 9.57 kg, p < 0.05). No signiﬁcant effect on feed to gain ratio was observed.
No raw data were provided for the feed intake.
Trial
no
Duration of
the trial
(days)
Total number of
animals
Additive CFU
(LAB/S. cerevisiae)/
kg feed(1)
Feed
intake
(kg)
Final
weight
(kg)
Feed:
gain
Mortality
(%)
No of replicates per
treatment 3 No of
animals per
replicate
3 35 160 0 n.r. 2.18a 1.59a 5
20 x 2 5 x 108/5 x 106 n.r. 2.35b 1.51b 5
5 x 109/5 x 107 n.r. 2.38b 1.50b 5
5.5 x 1010/5.5 x 108 n.r. 2.29b 1.50b 2.5
4 41 256 0 4.1 2.51 1.64 3
8 x 8 5 9 107 4.0 2.43 1.62 3
5 9 108 4.1 2.51 1.63 0
5 9 109 4.1 2.51 1.65 2
n.r. not reported; CFU: colony forming unit; LAB: lactic acid bacteria.
a, b: Means within a column with different superscript letters are signiﬁcantly different at p ≤ 0.05.
(1): In study 4, no differential values speciﬁed.
40 Technical dossier/Section IV and Supplementary information May 2015/Annexes IV.3 and 14 i 15/Annex 1415I.
41 Technical dossier/Supplementary information May 2015 and April 2016/Annex 14 i 15/Annex 1415II.
42 Technical dossier/Supplementary information May 2015/Annex 14 i 15/Annex 1415III.
43 Technical dossier/Supplementary information November 2015/Annex 8.
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The second study involved 112 turkeys (Big six, females, 1-day-old) divided into four treatments of
four replicates each (seven turkeys/pen).44 The treatments were either a negative control in which
animals received the basal diet without Lavipan® or three groups in which animals received diets
supplemented with Lavipan® to levels of LAB/S. cerevisiae of 5 x 108/5 x 106 CFU/kg (the
recommended dose), 5 x 109/5 x 107 CFU/kg or 5.5 x 1010/5.5 x 108 CFU/kg, respectively. All doses
were conﬁrmed by analysis of feed. Birds were fed a basal diet based on triticale/wheat/soybean/
maize during the 87 days of the trial. Birds were weighed every 2 weeks and feed intake, morbidity
and mortality were monitored during the whole experimental period. However, data on feed intake
were not provided. Feed to gain ratio was calculated. Data were analysed using ANOVA considering
the pen as experimental unit.
Mortality was low (1%) and not treatment related. The turkeys fed with Lavipan® at the
recommended dose showed signiﬁcantly greater ﬁnal body weights (7.94 vs 8.18 kg, p < 0.05) and
average daily weight gain (91 vs 93 g, p < 0.01) than those of the control group. No signiﬁcant effect
on feed to gain ratio was observed.
3.3.3.1. Conclusions on efﬁcacy for turkeys for fattening
Only two studies showed positive effects of the supplementation with the minimum recommended
dose in the performance of turkeys for fattening. Therefore, the FEEDAP Panel was not able to
conclude on the efﬁcacy of Lavipan® for turkeys for fattening based on the data available.
3.3.4. Compatibility with coccidiostats
MIC values were determined for the six coccidiostats (diclazuril, salinomycin sodium, decoquinate,
maduramicin and narasin+nicarbazin) for each of the bacterial strains present in Lavipan®.45 Values
were in all cases greater than four times the maximum authorised dose in feed. Therefore,
compatibility of Lc. lactis B/00039, C. divergens KKP 2012p, Lb. casei B/00080 and Lb. plantarum
B/00081 with diclazuril, salinomycin sodium, decoquinate, maduramicin and narasin+nicarbazin is
presumed.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation46 and Good
Manufacturing Practice.
4. Conclusions
The identity of the strains Lc. lactis B/00039, C. divergens KKP 2012p, Lb. casei B/00080,
Lb. plantarum B/00081 and S. cerevisiae KKP 2059p has been established. No antibiotic resistance of
concern has been detected for the bacterial strains. Following the QPS approach to safety assessment,
these strains are presumed safe for the target species, consumers of products from animals fed the
additive and the environment.
Lavipan® is not toxic by inhalation or a dermal/ocular irritant, but should be considered as a
potential respiratory sensitiser. In the absence of data, no conclusion can be drawn on the skin
sensitisation potential.
Lavipan® has the potential to improve the performance of chickens for fattening when
supplemented at the recommended dose of 5 x 108 CFU LAB/kg feed and 5 x 106 CFU S. cerevisiae/kg
feed. No conclusions can be drawn on the efﬁcacy of Lavipan® when added to feed for weaned piglets
or turkeys for fattening.
The use of Lavipan® is compatible with diclazuril, salinomycin, decoquinate, maduramicin and
narasin+nicarbazin.
44 Technical dossier/Supplementary information November 2015/Annex 9.
45 Technical dossier/Supplementary information November 2015/Annex 10.
46 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
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Documentation provided to EFSA
1) Lavipan® (Lactococcus lactis B/00039, Carnobacterium divergens KKP 2012p, Lactobacillus casei
B/00080, Lactobacillus plantarum B/00081 and Saccharomyces cerevisiae KKP 2059p) for
weaned piglets, chickens for fattening and turkeys for fattening. October 2013. Submitted by
JHJ LTD.
2) Lavipan® (Lactococcus lactis B/00039, Carnobacterium divergens KKP 2012p, Lactobacillus casei
B/00080, Lactobacillus plantarum B/00081 and Saccharomyces cerevisiae KKP 2059p) for
weaned piglets, chickens for fattening and turkeys for fattening. Supplementary information. May
2015 Year. Submitted by JHJ LTD.
3) Lavipan® (Lactococcus lactis B/00039, Carnobacterium divergens KKP 2012p, Lactobacillus casei
B/00080, Lactobacillus plantarum B/00081 and Saccharomyces cerevisiae KKP 2059p) for
weaned piglets, chickens for fattening and turkeys for fattening. Supplementary information.
November 2015. Submitted by JHJ LTD.
4) Lavipan® (Lactococcus lactis B/00039, Carnobacterium divergens KKP 2012p, Lactobacillus casei
B/00080, Lactobacillus plantarum B/00081 and Saccharomyces cerevisiae KKP 2059p) for
weaned piglets, chickens for fattening and turkeys for fattening. Supplementary information. April
2016. Submitted by JHJ LTD.
5) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods(s) of Analysis for Lavipan®.
6) Comments from Member States.
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Abbreviations
ANOVA analysis of variance
bw body weight
CEN European Committee for Standardization
CFU colony forming unit
CV coefﬁcient of variation
www.efsa.europa.eu/efsajournal 12 EFSA Journal 2016;14(9):4555
Lavipan® for weaned piglets, chickens and turkeys for fattening
EURL European Union Reference Laboratory
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
ISO International Organization for Standardization
LAB lactic acid bacteria
LOD limit of detection
MIC minimum inhibitory concentration
OECD Organisation for Economic Co-operation and Development
PCM Polish Collection of Microorgansims
PCR Polymerase Chain Reaction
PFGE Pulsed Field Gel Electrophoresis
RH relative humidity
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Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Method(s)
of Analysis for Lavipan®1
In the current application authorisation is sought under Article 4(1) for Lavipan® under the
category/functional group 4(b) ‘zootechnical additives’/‘gut ﬂora stabilisers’, according to Annex I of
Regulation (EC) No 1831/2003. Speciﬁcally, authorization is sought for the use of the feed additive for
piglets (weaned), chickens for fattening and turkeys for fattening.
According to the Applicant, the feed additive contains ﬁve non-genetically modiﬁed microorganisms:
Saccharomyces cerevisiae LOCK 0141, Lactococcus lactis IBB500, Carnobacterium divergens S1,
Lactobacillus casei LOCK 0915 and Lactobacillus plantarum LOCK 0862. The strain Lactococcus lactis
IBB500 is deposited at the Polish Collection of Microorganisms (PCM, Wroclaw, Poland), the strain
Carnobacterium divergens S1 is deposited at the Collection of Industrial Microorganisms (IAFB,
Warsaw) while the other three strains are deposited at the Centre of Industrial Microorganisms
Collection (LOCK, Lodz, Poland).
The product is intended to be marketed as a light cream to light brown powder containing at least
1 x 105 colony forming units (CFU) Saccharomyces cerevisiae LOCK 0141 per gram and a minimum of
1 x 107 CFU bacterial active substances per gram. The feed additive is intended to be used in
feedingstuffs at a minimum dose of 5 x 106 CFU of Saccharomyces cerevisiae LOCK 0141 per kg and
5 x 108 CFU of bacterial active substances per kg.
The Applicant used 16S rRNA gene sequence analysis for the identiﬁcation and characterisation of
the bacterial strains and internal transcribed spacer rRNA gene sequence analysis for the identiﬁcation
and characterisation of Saccharomyces cerevisiae LOCK 014. In addition, the Applicant referred to
Pulsed Field Gel Electrophoresis (PFGE), a generally recognised standard methodology for the genetic
identiﬁcation of the bacterial strains and to Polymerase Chain Reaction (PCR) for the identiﬁcation of
Saccharomyces cerevisiae LOCK 0141. The European Union Reference Laboratory (EURL) recommends
for ofﬁcial control these two methods (PFGE and PCR) for the identiﬁcation of the bacterial and yeast
strains.
For the enumeration of Lactococcus lactis IBB500, Carnobacterium divergens S1, Lactobacillus casei
LOCK 0915 and Lactobacillus plantarum LOCK 0862 in the feed additive and feedingstuffs the Applicant
submitted the ISO 15214 poured-plate method and demonstrated its suitability by providing
experimental data obtained in the frame of the stability study. The EURL identiﬁed instead, for the
enumeration of the Lactobacilli in the feed additive and feedingstuffs, the ring-trial validated spread
plate method EN 15787 for the enumeration in the feed additive and feedingstuffs.
For the enumeration of Saccharomyces cerevisiae LOCK 0141 in feed additive and feedingstuffs the
Applicant submitted the EN 15789 poured-plate method.
Based on the performance characteristics available the EURL recommends for ofﬁcial control the
ﬁve ring trial validated CEN and ISO methods mentioned above.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005) is not
considered necessary.
1 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/default/ﬁles/ﬁnrep-fad-2013-0048_Lavipan®_online.pdf
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